CTMXCytomX Therapeutics, Inc. — stock analysis & sentiment

At $3.10, the stock sits in the lower half of a 52-week range that runs from $1.72 to $8.21 — roughly 80% above the low and about 62% below the high. A band that wide, with the high nearly five times the low, describes a stock that has traded in large swings rather than a narrow channel over the past year, and the current price reflects a partial retracement from the upper end of that range rather than a settling near either extreme.

The market is valuing the business at about $680 million, or roughly 2.1 times book value. Conventional earnings multiples don't apply here: the forward P/E is negative at -6.4, and the profit margin of about -166% means losses currently exceed revenue, while revenue itself is down close to 80% year over year — the financial profile of a clinical-stage developer whose income is driven by collaboration payments rather than product sales. With a beta of 2.08, the shares have historically moved about twice as much as the broader market in both directions.

Recent news flow is mostly company-specific and centers on partnerships and capital. The most recent item is an expansion of the strategic research collaboration with Regeneron in conditional bispecific therapeutics, announced in June 2026; earlier in the year, in March 2026, the company priced a $250 million offering of common stock and pre-funded warrants. The remainder consists largely of routine investor-conference appearances and a quarterly results announcement, with only two broader healthcare-sector roundups in which the company appears alongside other names rather than as the subject.